Metraipolis › archive › dc_eb2c03ba6be8

A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in… — Europe PMC PMID:42342968

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42342968
DOI
10.1038/s41409-[numero omesso]-7
License (as archived)
solo-consultazione
Archived
2026-10-19T04:54:29.299Z
SHA-256 of the archived text
ee39369b37b59cc3ecfe10bbb05fb9f9c4939185f8a8ab6ae4b91106ab724bf3
Stable URL of this page
https://metraipolis.com/documento/dc_eb2c03ba6be8

How to cite

A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in… — Europe PMC PMID:42342968 — Europe PMC (en), https://europepmc.org/article/MED/42342968 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_eb2c03ba6be8 (Metraipolis archive dc_eb2c03ba6be8, sha256 ee39369b37b59cc3ecfe10bbb05fb9f9c4939185f8a8ab6ae4b91106ab724bf3)
BibTeX
@misc{dceb2c03ba6be8,
  title = {A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in… — Europe PMC PMID:42342968},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42342968},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_eb2c03ba6be8; sha256 ee39369b37b59cc3ecfe10bbb05fb9f9c4939185f8a8ab6ae4b91106ab724bf3},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42342968. Agents can read the archived copy with the MCP tool read_document.